The UBE3A/mH2A1/TERT axis enhances the anti-senescence capacity of pancreatic cancer cells and drives malignant progression, suggesting that UBE3A may serve as a novel therapeutic target for pancreatic cancer. Here, MACROH2A1 is linked to pancreatic neoplasm.